NASDAQ · FBRX
Forte Biosciences, Inc.
$76.99$0.00 (0.0%)
Forte Biosciences, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.27% below the high.
Loading market information…
NASDAQ · APLT · USD
Stock price, earnings
Quote as of Sep 4, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Applied Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 93.13% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Applied Therapeutics, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Applied Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing innovative treatments for cardiovascular conditions, galactosemia, and various diabetes-related complications. The company's primary drug candidate, AT-007, has successfully concluded Phase 1/2 studies for galactosemia in healthy adult volunteers and is presently in a pediatric clinical study for the same indication in children. Additionally, AT-007 is being investigated for its potential to address sorbitol dehydrogenase deficiency and phosphomannomutase enzyme-CDG. Another key compound, AT-001, is currently undergoing pivotal Phase III clinical trials. This therapy is being evaluated for its efficacy in treating both diabetic cardiomyopathy and diabetic peripheral neuropathy. Beyond its clinical pipeline, the company also maintains an early-stage preclinical portfolio. This includes AT-003, which is being developed for diabetic retinopathy, and AT-104. AT-104 is a PI3K inhibitor specifically designed to target T-Cell Acute Lymphoblastic Leukemia, a rare form of blood cancer. Applied Therapeutics, Inc. was established in 2016 and operates from its headquarters in New York City.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 08:25 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| $144.00K-94.24% vs estimate |
| Q1 2024 | May 9, 2024 | -$0.67-320.35% vs estimate | $190.00K-94.3% vs estimate |
|---|
| Q4 2023 | Mar 6, 2024 | -$0.40-114.2% vs estimate | -$667.00K-120.01% vs estimate |
|---|
THE ANALYST VIEW
11 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$76.99$0.00 (0.0%)
Forte Biosciences, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.27% below the high.
$2.41-$0.12 (-4.74%)
PepGen Inc.’s quoted price sits in the lower half of its reported 52-week range, 69.1% below the high.
$3.53-$0.18 (-4.88%)
Molecular Partners AG’s quoted price sits in the lower half of its reported 52-week range, 34.14% below the high.
$1.66-$0.06 (-3.49%)
Nkarta, Inc.’s quoted price sits in the lower half of its reported 52-week range, 55.38% below the high.
$0.79+$0.03 (+4.25%)
Milestone Pharmaceuticals Inc.’s quoted price sits in the lower half of its reported 52-week range, 74.2% below the high.
$4.22-$0.03 (-0.71%)
Corbus Pharmaceuticals Holdings, Inc.’s quoted price sits in the lower half of its reported 52-week range, 75.52% below the high.
$0.91+$0.01 (+1.6%)
Cardiff Oncology, Inc.’s quoted price sits in the lower half of its reported 52-week range, 72.45% below the high.
$1.32+$0.03 (+2.33%)
Cassava Sciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 73.49% below the high.
